Medicine
Tazicef 2 g powder for injection
Tazicef 2 g powder for injection is a prescription medicine containing Ceftazidime for intravenous use, marketed by Hospira, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Tazicef in the dry state should be stored at 20°C to 25°C (68°F to 77°F) and…
Key facts
- Active ingredient (INN)
- Ceftazidime
- Brand
- Tazicef
- Strength
- 2 g
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 10 vials
- Marketing authorisation holder
- Hospira
- Manufacturer
- Hospira
- Origin register
- US FDA, United States
- Storage
- Tazicef in the dry state should be stored at 20°C to 25°C (68°F to 77°F) and protected from light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J01DD02 Ceftazidime
- HS code (indicative)
- 3004.20Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 16 December 2005
- Identifiers
- RxCUI 1659283, 1659287, 1659292 +1DailyMed set ID 40d48c5d-650e-461b-a67b-7e65772d1b92NDC 0409-5084Application ANDA062662
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 10 vial, single-dose in 1 carton / 1 injection, powder, for solution in 1 vial, single-dose | 0409-5084-11 | Hospira | 16 December 2005 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 19 July 1985 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Ceftazidime 2 g powder for injection.
Other strengths and forms of Ceftazidime
Clinical summary
Ceftazidime is a cephalosporin antibacterial indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in diseases. It is available as powder for injection for intravenous and intramuscular use. MedsAcross supplies Ceftazidime for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about CeftazidimeFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Ceftazidime prescribing information (Sagent Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Tazicef 2 g powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.